You are viewing a single comment's thread from:
RE: Hemophilia - The most Sneaky disease | A Deep Analysis
You explained the physiology and the different variants extensively but were quite short on the medications (what affected people would be interested most in I guess). Most significantly there is a new, promising mode of action (instead factor replacement) led by Emicizumab which is given subcutanously instead of i.v. - a milestone in patient convenience.
Emicizumab
Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Chugai (a subsidiary of Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects.In November 2017, it was approved by the US FDA for treatment of haemophilia A in those who had developed resistance to other treatments. It was subsequently approved by the US FDA in April 2018 under the breakthrough therapy designation for treatment of haemophila A in those who have not developed resistance to other treatments.